Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.70 |
| ▸ | SHBG | P04278 | 5/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | AR | P10275 | 3/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.70 |
| ▸ | PGR | P06401 | 2/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | SNCA | P37840 | 2/20 | 0.70 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.70 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.70 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.70 |
| ▸ | ESR1 | P03372 | 1/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26333875 | 1.00 | CYP19A1 (0.70) | CYP19A1SHBGLMNAHSD17B10AR | |
| SCHEMBL12467452 | 0.84 | CYP19A1 (0.62) | CYP19A1SHBGLMNAHSD17B10AR | |
| SCHEMBL15661351 | 0.84 | CYP3A4 (0.74) | CYP19A1SHBGLMNAHSD17B10AR | |
| SCHEMBL12029018 | 0.84 | CYP3A4 (0.74) | CYP19A1SHBGLMNAHSD17B10AR | |
| SCHEMBL21119725 | 0.84 | CYP3A4 (0.74) | CYP19A1SHBGLMNAHSD17B10AR | |
| SCHEMBL11139019 | 0.84 | CYP3A4 (0.74) | CYP19A1SHBGLMNAHSD17B10AR | |
| SCHEMBL12029019 | 0.84 | CYP3A4 (0.74) | CYP19A1SHBGLMNAHSD17B10AR | |
| SCHEMBL7518415 | 0.83 | CYP19A1 (0.64) | CYP19A1SHBGLMNAHSD17B10AR | |
| SCHEMBL25117670 | 0.82 | CYP19A1 (0.73) | CYP19A1SHBGLMNAHSD17B10AR | |
| Epitestosterone SCHEMBL21957465 | 0.82 | AR (1.00) | CYP19A1SHBGLMNAHSD17B10AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103272231-A | Vaccine for immunizing sheep for producing twins and preparation method thereof | LANZHOU INST ANIMAL SCIENCE & VETERINARY PHARMACEUTICS CAAS | 2013-09-04 | — | — | CN | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| CN-101460846-A | Method for detecting modulators of membrane androgen receptor (mAR) | MEDEXIS S A (GR) | 2009-06-17 | — | — | CN | disclosed |
| US-20090104122-A1 | DETECTION OF MEMBRANE ANDROGEN RECEPTOR (mAR) AGENTS | MEDEXIS S.A. (GR) | 2009-04-23 | — | — | US | disclosed |
| EP-2008099-A2 | DETECTION OF MEMBRANE ANDROGEN RECEPTOR (MAR) AGENTS | Medexis S.A. (GR) | 2008-12-31 | — | — | EP | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007123682-A2 | DETECTION OF MEMBRANE ANDROGEN RECEPTOR (MAR) AGENTS | MEDEXIS S.A. (GR) | 2007-11-01 | — | — | WO | disclosed |
| US-4376825-A | ENZYME-BOUND LIGANDS WITH FREE REACTIVE SITES WHICH CAN BIND RECEPTORS | SYVA COMPANY (US) | 1983-03-15 | — | — | US | disclosed |
| US-4358435-A | Ligand compositions and processes for their manufacture and their use in radioimmunoassay | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1982-11-09 | — | — | US | disclosed |
| US-4323647-A | IMMOBILIZED ENZYMES SEPARATION | UNIVERSITY OF MIAMI (US) | 1982-04-06 | — | — | US | disclosed |
| US-4282325-A | FOR AMPLIFICATION IN ASSAYS | SYVA COMPANY (US) | 1981-08-04 | — | — | US | disclosed |
| US-4203802-A | ENZYME BOUND TO AN ESTROGEN LIGAND | SYVA COMPANY (US) | 1980-05-20 | — | — | US | disclosed |
| US-4190496-A | RECEPTOR, LIGAND, AND ENZYME-BOUND | SYVA COMPANY (US) | 1980-02-26 | — | — | US | disclosed |
| US-4067774-A | Compounds for enzyme amplification assay | SYVA COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
| US-3975237-A | LIGANDS | SYVA COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
| US-3968105-A | Prolonged release of antifertility drugs | IIT RESEARCH INSTITUTE (US) | 1976-07-06 | — | — | US | disclosed |
| US-3966764-A | ELECTRON SPIN RESONANCE | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966556-A | Compounds for enzyme amplification assay methadone analogs | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3966744-A | Spin labeled compounds | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | CYP19A1 1933/4885SHBG 595/4885LMNA 692/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | CYP19A1 1753/4885SHBG 1022/4885LMNA 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.